BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

FDA 's Norman Stockbridge wants to abandon thorough QT studies by 2015, replacing them with a preclinical assay suite better able to detect proarrhythmia side effects than existing assays. However, it remains unclear whether two...
BC Innovations | Jul 18, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Seizures Calcium channel voltage-dependent L type-a 1C subunit (CACNA1C; Cav1.2) Rodent and cell culture studies suggest inhibiting Cav1.2 could help treat...
BC Week In Review | Aug 13, 2012
Company News

Sigma-Aldrich, Autism Speaks deal

Sigma-Aldrich's Sigma Advanced Genetic Engineering (SAGE) Labs initiative and the advocacy group expanded a 2010 deal to develop rat models with modified autism-associated genes. Under the expansion, the partners will generate rat knockout models with...
BC Innovations | Sep 15, 2011
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of Timothy syndrome (TS) Mouse studies identified a genetic model of TS that could be used to identify new therapeutics for the form...
BC Innovations | Feb 10, 2011
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models In vitro model of long QT syndrome (LQTS) based on patient-derived induced pluripotent stem (iPS) cells Patient-derived iPS cells could be useful for screening compounds...
BC Innovations | Feb 10, 2011
Tools & Techniques

Models for QT prolongation

A group at the Technion Israel Institute of Technology and a team at the Stanford University School of Medicine have independently developed human stem cell-based models of long QT syndrome, 1,2 a potentially fatal cardiac...
Items per page:
1 - 6 of 6